Home › Compare › RTGOF vs ABBV
RTGOF yields 5128.21% · ABBV yields 3.06%● Live data
📍 RTGOF pulled ahead of the other in Year 1
Combined, RTGOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RTGOF + ABBV for your $10,000?
ArtGo Holdings Limited, an investment holding company, primarily engages in the mining, processing, trading, and sale of marble stones and commodity trading businesses in the People's Republic of China. It operates in two segments, Marble Products and Others. The company offers marble slabs, standard cut to size marble, antique series, water jet, border series, and marble-related crafts for bathroom and tailor-made household products; and calcium carbonate products. It also provides cargo handling services; and wholesales and retails decorating materials and chemical products. In addition, the company is involved in the provision of technical services for stone processing; warehousing, logistics, and sale of mineral products; and mining investment and mining planting projects. The company was formerly known as ArtGo Mining Holdings Limited and changed its name to ArtGo Holdings Limited in March 2015. ArtGo Holdings Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
Full RTGOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.